Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Status:
Recruiting
Trial end date:
2024-03-18
Target enrollment:
Participant gender:
Summary
This clinical trial is evaluating a drug called SNX281 given by itself and in combination
with pembrolizumab in participants with advanced solid tumors and lymphoma. The main goals of
this study are to:
- Find the recommended dose of SNX281 that can be given to participants safely alone and
in combination with pembrolizumab.
- Learn more about the side effects and safety profile of SNX281 alone and in combination
with pembrolizumab
- Learn more about pharmacological characteristics of SNX281 alone and in combination with
pembrolizumab
- Learn more about effectiveness of SNX281 alone and in combination with pembrolizumab